

HB 1036 -- LIMITS ON SELLING OR PURCHASING CERTAIN DRUGS

SPONSOR: Peters

COMMITTEE ACTION: Voted "Do Pass" by the Standing Committee on Health and Mental Health by a vote of 13 to 0.

Current law prohibits the sale, purchase, or dispensation of ephedrine, phenylpropanolamine, or pseudoephedrine to the same individual in a 12 month period in an amount greater than 43.2 grams. This bill changes that yearly limit to 61.2 grams.

The bill requires, beginning on October 1, 2025, any manufacturer of compounds, mixtures, or preparations specified in the bill to pay monthly fees to the administrator of the real-time electronic pseudoephedrine tracking system. The fee levels are to be set by the administrator.

This bill provides that a manufacturer commits the offense of unlawful sale, distribution, or purchase of over-the-counter methamphetamine precursor drugs if the manufacturer knowingly fails to pay the fees required by the provisions of this bill.

This bill is similar to HB 2824 (2024).

PROPONENTS: Supporters say that this bill will level the playing field for manufacturers, who will only be paying for the transactions described in the bill that are related to the manufacturer's product. Currently, in Missouri, the products are in essence subsidized by larger manufacturers.

Testifying in person for the bill were Representative Peters; Haleon; and Consumer Healthcare Products Association.

There was no opposition voiced in person to the committee.

Written testimony has been submitted for this bill. The full written testimony and witnesses testifying online can be found under Testimony on the bill page on the House website.